Acacia Technologies Expands Patent Licensing and Engineering Teams.NEWPORT BEACH, Calif. -- Acacia Research Corporation (Nasdaq:ACTG ACTG Acting ACTG AIDS Clinical Trial Group ACTG Actuating/Actuator )(Nasdaq:CBMX) announced today that its Acacia Technologies group, a technology licensing company, has expanded its patent licensing and engineering teams. Jeffrey Schoenwald, Ph.D. has joined the company as Vice President, Engineering and Julia Feldman has joined the company as Director, Licensing. Dr. Schoenwald has over thirty years of technical management experience with companies including Texas Instruments, Teledyne, Rockwell International and Boeing North America where his responsibilities included product development, device design, due diligence Research; analysis; your homework. This term has caught on in all industries, because it sounds so "wired." Who would want to do analysis or research when they can do due diligence. See wired. and patent search and development. Dr. Schoenwald has published seventy research and technical marketing papers and is a named inventor of eight patents. He holds a B.S. from the Massachusetts Institute of Technology Massachusetts Institute of Technology, at Cambridge; coeducational; chartered 1861, opened 1865 in Boston, moved 1916. It has long been recognized as an outstanding technological institute and its Sloan School of Management has notable programs in business, and M.S. and Ph.D. degrees from the University of Pennsylvania (body, education) University of Pennsylvania - The home of ENIAC and Machiavelli. http://upenn.edu/. Address: Philadelphia, PA, USA. . Ms. Feldman was most recently an attorney in the Intellectual Property Licensing Department of Discovision Associates, a subsidiary of Pioneer Electronics, where she negotiated intellectual property license and settlement agreements as well as technology purchase agreements. Prior to joining Discovision Associates, Ms. Feldman was an associate with Stradling, Yocca, Carlson & Rauth. Ms. Feldman holds a B.A. degree from The George Washington University George Washington University, at Washington, D.C.; coeducational; chartered 1821 as Columbian College (one of the first nonsectarian colleges), opened 1822, became a university in 1873, renamed 1904. and a J.D. degree from The Georgetown University Law Center Also attended
Paul Ryan, Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. commented, "Dr. Schoenwald and Ms. Feldman are great additions to our engineering and licensing teams as we continue to expand our technology licensing business. Dr. Schoenwald's broad technology background will be extremely valuable in identifying and selecting the patented technologies that we acquire for out-licensing. Ms. Feldman's initial licensing responsibilities will include our recently acquired Internet Access Redirection ("IAR IAR - Instruction Address Register. The IBM name for program counter. ") patent, which has licensing opportunities for wireless 'hotspots' and hotel high-speed Internet access." Acacia has entered into 170 license agreements for its Digital Media Transmission (DMT See DSL. (R)) technology for cable TV, corporate websites, e-learning, hotel on-demand TV services, and online entertainment, movies, music, news, and sports. ABOUT ACACIA RESEARCH CORPORATION Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group. The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia's DMT(R) technology, which is supported by 5 U.S. and 31 foreign patents, relates to audio and audio/video transmission and receiving systems commonly known as audio-on-demand, video-on-demand, and audio/video streaming, and is used for distributing digital content via several means including Internet, cable, satellite and wireless systems. The CombiMatrix group is developing a platform technology to rapidly produce customizable active biochips, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. CombiMatrix's technology has a wide range of applications including DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. synthesis/diagnostics, drug discovery, and immunochemical im·mu·no·chem·is·try n. The chemistry of immunologic phenomena, as of antigen-antibody reactions. im detection. CombiMatrix's Express Track(sm) drug discovery program is a systems biology approach, using its technology, to target common viral diseases with siRNA compounds. Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups. Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion